BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 30670443)

  • 1. MDS overlap disorders and diagnostic boundaries.
    Tanaka TN; Bejar R
    Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
    Valent P
    Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of dysplastic changes in acquired aplastic anemia: A systematic study of bone marrow biopsies in children and adults.
    Marchesi RF; Velloso EDRP; Garanito MP; Leal AM; Siqueira SAC; Azevedo Neto RS; Rocha V; Zerbini MCN
    Ann Diagn Pathol; 2020 Apr; 45():151459. PubMed ID: 32000075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
    Malcovati L; Cazzola M
    Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?
    Barrett J; Saunthararajah Y; Molldrem J
    Semin Hematol; 2000 Jan; 37(1):15-29. PubMed ID: 10676908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
    Padron E
    Hematology Am Soc Hematol Educ Program; 2015; 2015():349-54. PubMed ID: 26637742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
    Hasserjian RP; Buckstein R; Patnaik MM
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms.
    Bennett JM
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):607-609. PubMed ID: 27693133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and treatment of childhood myelodysplastic syndrome].
    Hasegawa D
    Rinsho Ketsueki; 2021; 62(4):229-238. PubMed ID: 33967145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and classification of myelodysplastic syndromes.
    Hasserjian RP; Germing U; Malcovati L
    Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of clonal hematopoiesis and disease boundaries in bone marrow failure diseases].
    Suzuki T
    Rinsho Ketsueki; 2023; 64(6):474-481. PubMed ID: 37407470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
    DeZern AE; Malcovati L; Ebert BL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Special Education: Aplastic Anemia.
    Teramura M; Mizoguchi H
    Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.
    Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Dworzak M; Hasle H; Locatelli F; De Moerloose B; Schmugge M; Mejstrikova E; Nováková M; Zecca M; Zwaan CM; Te Marvelde JG; Langerak AW; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH
    Haematologica; 2015 Mar; 100(3):315-23. PubMed ID: 25425683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
    AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What biologic factors predict for transformation to AML?
    Bejar R
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.